New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline wi

Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists March 19, 2026 -- Endevica Bio, a privately-held company developing first-in-class synthetic peptidomimetics, toda

Strategy May Bolster Blood Cancer Therapy and Move HIV Research Closer to a Cure March 13, 2026 -- A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments. Their findings, published today in Science Advances, describe a manufacturing approach that, compared to the existing

A new synthesis finds that common epilepsies are driven by thousands of tiny-effect genetic variants, most still undetected. March 10, 2026 --- An insightful mini-review published in Genomic Psychiatry synthesizes the rapidly expanding landscape of molecular genetic research on common epilepsies, assembling evidence from genome-wide association studies (large-scale genetic scans across the human genome), whole-exome sequencing projects, and advanced statistical modeling to illuminate the polyge

Mayo Clinic researchers have identified a rare mutation in the MET gene that can directly cause metabolic dysfunction-associated steatotic liver disease. The mutation disrupts the liver’s ability to process fat, leading to inflammation, scarring, and potentially cirrhosis. The discovery began with a father and daughter who had the disease without typical risk factors. Large-scale genomic data suggests similar rare variants may quietly contribute to the disease in many more people. Scientists at

March 3, 2026 -- Linus Health will present new research at a leading global Alzheimer's and Parkinson's Diseases conference, revealing how advanced insights from digital cognitive assessments and personalized outcome measures may help transform how patients are identified for emerging therapies and how treatment impact is measured in ways that reflect patients' personal priorities. This research will be presented at the International Conference on Alzheimer's and Parkinson's Diseases and Relate

Feb. 23, 2026 -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports. The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Com

81.8% of patients with bothersome tinnitus treated with Lenire at New York Hearing Doctors reported significant improvement in a real-world clinical setting.1,2 Patients with bothersome tinnitus reported a 23.8 point mean reduction in tinnitus as measured by the Tinnitus Handicap Inventory, which is greater than three times the threshold for clinical significance.1,2 The majority of patients with bothersome tinnitus reported they were no longer severely impacted by their tinnitus following 12-we

Feb. 13, 2026-- A newly published scientific paper titled " Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration. Int. J. Mol. Sci. 2025, 26, 10969. https://doi.org/10.3390/ijms262210969) has validated a groundbreaking mechanism that has been at the core of HYD LLC for Cancer Research and Drug

Feb. 10, 2026 -- The increased size of, and lesser blood supply to, a key brain structure in patients with Long COVID tracks with known blood markers of Alzheimer's disease and greater levels of dementia, a new study finds. Led by NYU Langone Health researchers, the study concerns the choroid plexus (CP), a network of blood vessels lined by cells that produce cerebrospinal fluid, which cushions the brain and forms a protective barrier between the fluid and the bloodstream. The CP regulates imm